13F Holdings
中文EN

STOK Stoke Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1623526 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-86.3%
TTM net income YoY-699.5%
TTM EPS YoY-655.9%
Revenue 3-yr CAGR45.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-913.1%
Net margin-862.1%
FCF margin-764.7%
EBITDA margin-906.9%

Returns

ROE-73.6%
ROA-63.4%
ROIC (approx.)-86.6%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets13.3%
Debt / equity0.00x
Current ratio7.24x
Interest coverage-4,088.90x

Cash quality & payout

Operating cash flow / net income0.86x
Accruals ratio-8.6%
Payout ratio—
Capex / revenue19.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$184.42M$36.55M$8.78M$12.40M—
R&D expense$137.92M$89.13M$82.23M$77.84M$54.17M
SG&A expense$67.09M$48.79M$41.32M$38.92M$31.90M
Operating income-$20.59M-$101.37M-$114.77M-$104.36M-$86.06M
Interest expense$9,000$26,000$49,000——
Income tax$0————
Net income-$6.88M-$88.98M-$104.70M-$101.07M-$85.81M
EBITDA-$18.82M-$99.19M-$112.30M-$102.81M-$85.09M
EPS (basic)-0.12-1.65-2.38-2.60-2.34
EPS (diluted)-0.12-1.65-2.38-2.60-2.34
Weighted avg. shares (diluted)59.22M54.01M43.99M38.90M36.74M
Balance sheet
Cash & equivalents$84.22M$127.98M$191.44M$113.56M$144.90M
Short-term investments$200.45M$88.92M$9.95M$116.04M$74.92M
Receivables$5.94M$1.67M———
Current assets$305.70M$232.76M$215.34M$244.07M$229.22M
PP&E, net$3.15M$3.91M$5.82M$6.67M$4.14M
Total assets$418.43M$271.56M$228.34M$256.07M$238.87M
Current liabilities$57.88M$40.06M$30.82M$31.39M$17.14M
Total liabilities$65.98M$42.53M$68.78M$71.22M$21.09M
Shareholders' equity$352.46M$229.02M$159.56M$184.85M$217.78M
Shares outstanding58.92M54.03M45.92M39.44M36.90M
Cash flow statement
Operating cash flow$45.59M-$86.85M-$81.07M-$31.87M-$66.91M
Capital expenditure$670,000$203,000$1.62M$3.96M$1.20M
Free cash flow$44.91M-$87.05M-$82.68M-$35.83M-$68.11M
Investing cash flow-$186.81M-$107.47M$105.95M-$45.88M-$76.43M
Financing cash flow$97.39M$131.09M$53.01M$46.41M$1.28M
Depreciation & amortization$1.77M$2.18M$2.47M$1.55M$974,000
Stock-based compensation$32.24M$27.47M$25.26M$22.85M$16.45M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.